​

C4 Therapeutics (CCCC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CCCC Stock Forecast

C4 Therapeutics (CCCC) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $8.67, with a high of $10.00 and a low of $6.00. This represents a 236.05% increase from the last price of $2.58.

$2 $3 $4 $5 $6 $7 $8 $9 $10 $11 High: $10 Avg: $8.67 Low: $6 Last Closed Price: $2.58

CCCC Stock Rating

C4 Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (71.43%), 3 Hold (21.43%), 1 Sell (7.14%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 3 10 Strong Sell Sell Hold Buy Strong Buy

CCCC Price Target Upside V Benchmarks

TypeNameUpside
StockC4 Therapeutics236.05%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-45
Avg Price Target-$8.50$9.20
Last Closing Price$2.58$2.58$2.58
Upside/Downside-229.46%256.59%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25161--8
Sep, 25-42--6
Aug, 25-42--6
Jul, 25-43--7
Jun, 25-44--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 23, 2025Derek ArchilaWells Fargo$10.00$2.80257.14%287.60%
Sep 22, 2025Etzer DaroutBarclays$10.00$3.16216.46%287.60%
Sep 16, 2025Barclays$8.00$3.41134.60%210.08%
Sep 15, 2025Sudan LoganathanStephens$6.00$3.5768.07%132.56%
Dec 19, 2024Derek ArchilaWells Fargo$12.00$4.31178.42%365.12%
Sep 19, 2024Etzer DaroutBMO Capital$20.00$6.87191.12%675.19%
Jan 03, 2023Wells Fargo$9.00$6.3142.63%248.84%
Apr 28, 2022Credit Suisse$10.00$8.8512.99%287.60%
Apr 11, 2022Chi FongBank of America Securities$15.00$8.0187.27%481.40%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 23, 2025Wells FargoOverweightOverweighthold
Sep 22, 2025BarclaysOverweightOverweighthold
Sep 16, 2025BarclaysOverweightinitialise
Sep 15, 2025StephensOverweightupgrade
Sep 03, 2025GuggenheimBuyinitialise
Dec 19, 2024Wells FargoEqual-WeightOverweightupgrade
Sep 19, 2024BMO CapitalOutperformOutperformhold
Dec 13, 2023Piper SandlerBuyupgrade
Feb 24, 2023Credit SuisseUnderperformNeutralupgrade
Jan 03, 2023Wells FargoEqual-WeightEqual-Weighthold

Financial Forecast

EPS Forecast

$-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$-1.54$-1.87$-2.59$-2.67-
Avg Forecast$-7.94$-2.05$-2.59$-2.60$-1.49
High Forecast$-7.94$-2.05$-2.59$-2.33$-1.41
Low Forecast$-7.94$-2.05$-2.59$-2.86$-1.58
Surprise %-80.60%-8.78%-2.69%-

Revenue Forecast

$15M $22M $29M $36M $43M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$33.20M$45.78M$31.10M$20.76M-
Avg Forecast$32.92M$33.08M$39.80M$21.45M$35.79M
High Forecast$32.92M$33.08M$39.80M$28.59M$40.79M
Low Forecast$32.92M$33.08M$39.80M$17.13M$30.29M
Surprise %0.85%38.40%-21.86%-3.25%-

Net Income Forecast

$-400M $-330M $-260M $-190M $-120M $-50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$-66.33M$-86.04M$-126.50M$-132.49M-
Avg Forecast$-394.27M$-100.64M$-117.73M$-132.49M$-74.23M
High Forecast$-394.27M$-80.51M$-94.18M$-105.99M$-70.10M
Low Forecast$-394.27M$-120.76M$-141.28M$-158.99M$-78.37M
Surprise %-83.18%-14.51%7.45%--

CCCC Forecast FAQ

Is C4 Therapeutics stock a buy?

C4 Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that C4 Therapeutics is a favorable investment for most analysts.

What is C4 Therapeutics's price target?

C4 Therapeutics's price target, set by 14 Wall Street analysts, averages $8.67 over the next 12 months. The price target range spans from $6 at the low end to $10 at the high end, suggesting a potential 236.05% change from the previous closing price of $2.58.

How does C4 Therapeutics stock forecast compare to its benchmarks?

C4 Therapeutics's stock forecast shows a 236.05% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for C4 Therapeutics over the past three months?

  • October 2025: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is C4 Therapeutics’s EPS forecast?

C4 Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.49, marking a -44.19% decrease from the reported $-2.67 in 2023..

What is C4 Therapeutics’s revenue forecast?

C4 Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $35.79M, reflecting a 72.43% increase from the reported $20.76M in 2023.

What is C4 Therapeutics’s net income forecast?

C4 Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-74.235M, representing a -43.97% decrease from the reported $-132M in 2023.